Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Vimian Group AB ( (SE:VIMIAN) ) is now available.
Vimian Group AB has been awarded USD 40.2 million by the Superior Court of Delaware in an indemnification dispute related to its subsidiary, Veterinary Orthopedic Implants, LLC (VOI). This decision follows a USD 70 million settlement Vimian paid to DePuy Synthes in a patent dispute in April 2023. The court’s decision, combined with previous settlements with other sellers, ensures Vimian recoups more than the initial settlement amount, positively impacting its financial standing and providing a resolution to the acquisition-related indemnification process.
The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian is a global animal health company operating in four key areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company is headquartered in Stockholm, Sweden, and serves over 17,000 veterinary clinics and laboratories across more than 80 markets. Vimian employs 1,200 people and generates annual revenues of approximately EUR 375 million.
Average Trading Volume: 639,301
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK16.6B
For a thorough assessment of VIMIAN stock, go to TipRanks’ Stock Analysis page.